MSD

News

MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.

News

A single year of adjuvant treatment with AstraZeneca and MSD's PARP inhibitor Lynparza is still providing a survival benefit six years later.

News

After a string of trial failures, MSD claims a partial win for Keytruda and Lynparza in advanced epithelial ovarian cancer.

News

The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.

News

Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China

News

ZENITH trial of MSD's Winrevair in PAH could add further momentum to an already impressive launch